Erik De Blois
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Radiobiological comparison of holmium-166 and yttrium-90 for hepatocellular carcinoma treatment in vitro.
Journal: Nuclear medicine communications
Published: February 26, 2026
Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 16, 2025
Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model.
Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model.
Journal: EJNMMI research
Published: December 01, 2025
Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [177Lu]Lu-PSMA-I&T.
Journal: EJNMMI radiopharmacy and chemistry
Published: October 03, 2025
Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 17, 2025
Ac-225 radiochemistry through the lens of [225Ac]Ac-DOTA-TATE.
Journal: EJNMMI radiopharmacy and chemistry
Published: December 13, 2024
IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals.
Journal: Nuclear medicine and biology
Published: November 14, 2024
First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 01, 2024
Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
Journal: BMC cancer
Published: January 10, 2024
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.
Journal: EJNMMI radiopharmacy and chemistry
Published: July 20, 2023
[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 09, 2023
Improved postprocessing of dynamic glucose-enhanced CEST MRI for imaging brain metastases at 3 T.
Journal: European radiology experimental
Published: June 06, 2023
Last Updated: 09/26/2026